The symptoms of a possible overdose may include rapid heartbeat, changes in level of consciousness (ranging from drowsiness to coma), blurred vision, seizures or attacks, and vomiting.
If you have not taken a dose, take it as soon as you remember. However, if it is already time for your next dose, skip the missed dose and take only one dose as usual. Do not take a double dose to compensate for the missed doses. Do not take more than the daily dose of Dobupal that has been prescribed to you in a day.
Do not stop taking your treatment or reduce the dose without consulting your doctor, even if you feel better. If your doctor thinks you no longer need Dobupal, they may ask you to gradually reduce the dose before stopping treatment completely. It is known that adverse effects occur when people stop using this medication, especially when it is stopped suddenly or if the dose is reduced very quickly. Some patients may experience symptoms such as suicidal thoughts, aggression, fatigue, dizziness, lack of stability, headaches, insomnia, nightmares, dry mouth, loss of appetite, nausea, diarrhea, nervousness, agitation, confusion, ringing in the ears, tingling or, in rare cases, electric shock sensations, weakness, sweating, seizures or symptoms similar to the flu, vision problems, and increased blood pressure (which can cause headaches, dizziness, ringing in the ears, sweating, etc.).
Your doctor will advise you on how to gradually stop treatment with Dobupal. This may take several weeks or months. In some patients, the interruption may need to be produced very gradually over months or more. If you experience any of these or other symptoms that bother you, consult your doctor for advice.
If you have any other doubts about the use of this medication, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everyone will experience them.
If any of the following effects occur, do not take any more Dobupal.Inform your doctor immediately, or go to the nearest hospital emergency room:
Rare (may affect up to 1 in 100 people)
Uncommon (may affect up to 1 in 1,000 people)
In its most severe form, serotonin syndrome may resemble Malignant Neuroleptic Syndrome (MNS). The signs and symptoms of MNS may include a combination of fever, rapid heartbeat, sweating, severe muscle rigidity, confusion, increased muscle enzymes (determined by blood tests).
Unknown frequency (cannot be estimated from available data)
Other side effects that you should inform your doctor are (the frequency of these side effects are included in the list below "other side effects that may occur"):
Very common (may affect more than 1 in 10 people)
Common (may affect up to 1 in 10 people)
Rare (may affect up to 1 in 100 people)
Rare (may affect up to 1 in 1,000 people)
Very rare (may affect up to 1 in 10,000 people)
Unknown frequency (cannot be estimated from available data)
Dobupal may sometimes cause unwanted effects that you may not be aware of, such as increased blood pressure or abnormal heartbeat; mild changes in liver enzyme levels, sodium, or cholesterol. Less frequently, Dobupal may reduce the function of platelets in the blood, leading to an increased risk of petechiae or bleeding. Therefore, your doctor may wish to perform occasional blood tests, particularly if you have been taking Dobupal for a long time.
Reporting of side effects
If you experience any type of side effect, consult your doctor, pharmacist, or nurse, even if it is a possible side effect that does not appear in this leaflet. You can also report them directly through the Spanish System for the Vigilance of Medicinal Products for Human Use, Website:www.notificaram.es.By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the packaging. The expiration date is the last day of the month indicated.
No special storage conditions are required.Store in a dry place.
Medications should not be disposed of through drains or in the trash.Deposit empty packaging and unused medications at the SIGRE collection pointat your pharmacy. If in doubt, ask your pharmacist how to dispose of unused packaging and medications. By doing so, you will help protect the environment.
Composition of Dobupal 37.5 mg tablets
The active ingredient is venlafaxine. Each tablet contains 42.42 mg of venlafaxine hydrochloride equivalent to 37.5 mg of venlafaxine base.
The other components (excipients) are: lactose, microcrystalline cellulose, sodium carboxymethyl starch, magnesium stearate, yellow iron oxide (E-172), and brown iron oxide (E-172).
Appearance of Dobupal and content of the packaging
Dobupal 37.5 mg is presented in the form of tablets. The tablets are circular, biplanar, with beveled edges and salmon-colored.
Dobupal 37.5 mg is presented in packaging containing 60 tablets for oral administration.
Holder of the marketing authorization and responsible for manufacturing
Holder of the marketing authorization
Almirall, S.A.
General Mitre, 151
08022 – Barcelona
Responsible for manufacturing
Industrias Farmacéuticas Almirall, S.A.
Ctra. de Martorell, 41-61
08740 Sant Andreu de la Barca – Barcelona (Spain)
This medicinal product was authorized in the Member States of the EEA with the following names:
Spain: Dobupal 37.5 mg tablets
Date of the last review of this leaflet:May 2023
The detailed and updated information on this medicinal product is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS)http://www.aemps.gob.es/
Маєте питання щодо цього лікування або ваших симптомів? Зв'яжіться з ліцензованим лікарем для отримання допомоги та персонального догляду.